Risperdal drives Janssen's advance in Japan

摘要

Good growth for mainstay products including Risperdal (risperidone) for schizophrenia and Durotep (transdermal fentanyl) for cancer pain drove calendar 2005 sales at Janssen Pharma in Japan up by 15.9% to ?83.8 billion (dollar712 million) at ex-factory prices. The Johnson & Johnson company was helped by improved growth in the country's overall drug market, although new formulations aided Risperdal's advance. The subsidiary did not release detailed sales data, noting only that the product grew by 21 %. Based on sales estimates for 2004, this would equate to around ?29 billion.